PTJ
LABP

Paul Tudor Jones’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Paul Tudor Jones’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,779
Closed -$206K – 2919
2021
Q2 		$206K Sell
1,779
-4,411
-71% -$492K ﹤0.01% 1487
2021
Q1 		$596K Buy
+6,190
New +$808K 0.01% 1072

Other funds holding LABP

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Paul Tudor Jones's LABP Position: Q3 2021 in Review

Paul Tudor Jones sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q3 2021, closing a stake of 1,779 shares — an estimated $206K sold.

Paul Tudor Jones first reported a position in LABP in Q1 2021 and held it in 2 quarters. The position peaked at $596K in Q1 2021. 35 funds tracked by Wall St. Rank hold LABP as of Q3 2021.

  • Paul Tudor Jones reported no remaining Landos Biopharma, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 1,779 Landos Biopharma, Inc. Common Stock shares in Q3 2021, an estimated $206K.
  • Paul Tudor Jones first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Paul Tudor Jones's Landos Biopharma, Inc. Common Stock position peaked at $596K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.